Cargando…
Barriers to Oncology Biosimilars Uptake in the United States
Biosimilars are biological compounds that contain an active substance that is similar to the active substance in an already approved biologic. This commentary focuses on the barriers to the use of biosimilars in the United States.
Autores principales: | Nabhan, Chadi, Valley, Amy, Feinberg, Bruce A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AlphaMed Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291332/ https://www.ncbi.nlm.nih.gov/pubmed/30049886 http://dx.doi.org/10.1634/theoncologist.2018-0066 |
Ejemplares similares
-
Greater uptake, an alternative reimbursement methodology needed to realize cost-saving potential of oncology biosimilars in the United States
por: Yang, Jingyan, et al.
Publicado: (2021) -
Biosimilars in the United States: Considerations for Oncology Advanced Practitioners
por: Mayden, Kelley D., et al.
Publicado: (2015) -
Assessing Clinical Equivalence in Oncology Biosimilar Trials With Time-to-Event Outcomes
por: Uno, Hajime, et al.
Publicado: (2019) -
Biosimilars in oncology
por: Tabernero, Josep
Publicado: (2018) -
Biosimilar and interchangeable: Inseparable scientific concepts?
por: de Mora, Fernando, et al.
Publicado: (2019)